FRACTYL HEALTH, INC. 8-K

What Happened

• On March 24, 2026, Fractyl Health, Inc. (NASDAQ: GUTS) announced its financial results for the quarter and full year ended December 31, 2025 and provided a corporate update. The company furnished a related press release as Exhibit 99.1 to the Form 8-K.
• The company also updated its investor-facing corporate presentation and a presentation summarizing REMAIN-1 Midpoint Cohort 6-month results to add new post hoc analyses exploring the relationship between treatment effect, procedural dose (length of duodenal ablation) and the degree of GLP‑1–induced weight loss prior to Revita® treatment. Updated slides are posted under “Events & Presentations” in the “Investor Overview” section of Fractyl’s website.

Key Details

• Filing date: March 24, 2026 (Current Report on Form 8-K).
• Reporting period: quarter and full year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to the 8-K (information furnished, not filed).
• Updated REMAIN-1 presentation includes post hoc analyses on procedural dose (duodenal ablation length) and interaction with prior GLP‑1–related weight loss for Revita® patients.

Why It Matters

• The 8-K provides investors with the company’s latest quarterly and full-year financial results and an official corporate update, which are important for assessing near-term performance and outlook.
• The updated REMAIN-1 analyses give additional clinical context on how procedure characteristics and prior GLP‑1–induced weight loss relate to treatment effect for Revita®, information that could be relevant to clinical development decisions and investor assessment of the therapy’s potential.
• All updated materials and the press release are available on Fractyl’s investor website for review.